This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Investigation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Routine screening should be done in all infants.

  • in UK, filter paper blood spot TSH measurement is used for screening - the TSH is high and diagnostic in primary hypothyroidism but normal or low in secondary hypothyroidism
    • the test is restricted to specialist centers
    • to avoid false positive results (since increased TSH levels are seen up to 24h following birth) the sample should be taken at least 48 hours after birth (within 2-8 day ) (1)
  • confirmatory examinations of congenital hypothyroidism:
    • should be done immediately after the TSH screening test (around 2 weeks after birth)
    • measure serum TSH and free T4 levels
      • increased serum TSH and a low free T4 or total free T4 indicates the diagnosis of primary hypothyroidism (2)
  • radiology may reveal delay in ossification and fragmentation of the epiphyses
  • radioactive marker uptake may be used to locate ectopic glands

Note:

  • in preterm infants or acutely ill term infants with primary hypothyroidism, increased TSH levels may not be detected during the first screening test
    • such infants are required to undergo a routine second screening test which will identify these infants with "delayed TSH rise"
    • present in approximately 1:18,000 newborns (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.